首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗臨床開發

市場調查報告書

商品編碼

1859699

人工智慧在臨床試驗中的應用：全球市場

Global Artificial Intelligence (AI) in Clinical Trials Market

出版日期: 2025年10月29日 | 出版商:

BCC Research | 英文 153 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球臨床試驗人工智慧市場預計將從 2024 年的 20 億美元和 2025 年的 24 億美元成長到 2030 年的 65 億美元，預測期內複合年成長率為 22.6%。

預計北美市場規模將從2024年的7.712億美元成長至2025年的9.367億美元，到2030年達到27億美元，複合年成長率為23.7%。預計亞太市場規模將從2024年的3.728億美元成長至2025年的4.679億美元，到2030年達到16億美元，複合年成長率為28.4%。

本報告調查了全球人工智慧在臨床試驗中的市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測，以及按各個細分市場和地區進行的詳細分析。

概述
未來展望
宏觀經濟因素
世界GDP成長率
人口統計因素
美國關稅的影響
波特五力分析
人工智慧對臨床試驗市場的影響
用例/案例研究
人工智慧應用：臨床試驗
區域/國家層面的採用趨勢
人工智慧帶來的顛覆性變革趨勢
人工智慧將如何影響產業
人工智慧如何影響價值鏈
市場支出和投資
市場支出及預測分析
專注於臨床試驗的創業投資創投

第3章市場動態

市場促進因素
需要加速藥物研發進程
人工智慧驅動的臨床試驗
針對複雜臨床輸入的高階資料處理
市場限制
資料隱私和安全問題
監理不確定性
高成本且技術複雜
市場機遇
自適應人工智慧設計加速測試
人工智慧驅動的遠端患者監護

第4章：監理現狀

法律規範

第5章新興技術

概述
新興技術
機器學習在預測分析和分層的應用
數位雙胞胎技術
利用自然語言處理技術從非結構化資料中提取洞見
人工智慧驅動的測試設計與最佳化
區塊鏈技術用於安全的臨床資料管理
分散式虛擬測試平台
利用穿戴式科技進行遠端監控
用於通訊協定創建的生成式人工智慧
將真實世界證據整合到臨床試驗中
可擴展部署的雲端基礎人工智慧平台
臨床試驗分析
摘要

第6章市場區隔分析

細分市場分析
全球臨床試驗人工智慧市場（按組件分類）
摘要
軟體
服務
全球人工智慧在臨床試驗中的市場按階段分類
摘要
第三階段
第二階段
第一階段
第四階段
全球人工智慧在臨床試驗中的市場按實施類型分類
摘要
雲
本地部署
混合部署
全球人工智慧在臨床試驗中的市場（按治療領域分類）
摘要
瘤
感染疾病臨床試驗
神經系統疾病
其他
全球臨床試驗人工智慧市場（按最終用戶分類）
摘要
製藥和生物技術公司
CRO
研究和學術機構
其他最終用戶
地理細分
北美洲
歐洲
亞太地區
中東和非洲
南美洲

第7章競爭訊息

第8章人工智慧在臨床試驗中的永續性：ESG視角

永續性趨勢與人工智慧舉措
結論

第9章附錄

調查方法
來源
簡稱
公司簡介
AICURE
CONCERTAI
DNANEXUS INC.
INSILICO MEDICINE
INTELLIGENCIA AI
IQVIA
MEDIDATA
MERATIVE
NVIDIA CORP.
PHESI
SAAMA
TEMPUS
TRINETX LLC
TRIOMICS
UNLEARN.AI INC.
Start-Ups創業公司/市場顛覆者

簡介目錄圖表

Product Code: PHM285A

The global market for Artificial Intelligence (AI) in Clinical Trials was valued at $2 billion in 2024 and is estimated to increase from $2.4 billion in 2025 to reach $6.5 billion by 2030, at a compound annual growth rate (CAGR) of 22.6% from 2025 through 2030.

The North American market for AI in Clinical Trials was valued at $771.2 million in 2024 and is estimated to increase from $936.7 million in 2025 to reach $2.7 billion by 2030, at a CAGR of 23.7% from 2025 through 2030.

The Asia-Pacific market for AI in Clinical Trials was valued at $372.8 million in 2024 and is estimated to increase from $467.9 million in 2025 to reach $1.6 billion by 2030, at a CAGR of 28.4% from 2025 through 2030.

Report Scope

The report examines trends in the global market for AI in clinical trials. It segments the global market by component, phase, deployment mode, therapeutic area and end user. It also provides insights into key emerging trends and potential growth drivers. Components consist of software and services. Deployment mode include cloud, on-premise, and hybrid. Therapeutic areas include cancers, infectious diseases and neurological diseases. End users include pharmaceutical and biotech companies, contract research organizations (CROs), and research and academic institutes.

The report's regional analysis covers North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. It evaluates the impact of AI adoption in clinical trials and the market dynamics, including drivers and challenges. The study concludes with an analysis of leading companies in the market and their product portfolios.

It includes global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

Report Includes

56 data tables and 52 additional tables
In-depth analysis of the global market for artificial intelligence (AI) in pharmaceutical clinical trials
Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
Estimates of the market's size and revenue growth prospects, accompanied by a market share analysis by offerings, deployment type, trial phase, therapeutic area, end user and region
Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
Impact analysis of U.S. tariff laws on AI in the clinical trials market
Insights derived from Porter's Five Forces model, as well as a global supply chain analysis
A look at the regulatory landscape featuring key international and regional regulations and standards for AI adoption
Evaluation of recent patent activity and key granted and published patents
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Company profiles of major players within the industry, including IQVIA, Medidata, Saama, Merative, and Nvidia Corp.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Future Outlook
Macroeconomic Factors
Global GDP Growth
Demographic Factors
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Impact of AI Adoption on Clinical Trials Market
Overview
Use Cases/Case Studies
Use Case 1: Oncology Patient Recruitment
Use Case 2: Accelerating Data Processing in Infectious Disease Vaccine Trials
Use Case 3: Enhancing Patient Retention in Alzheimer's Disease Trials
AI Adoption: Clinical Trials
Adoption Trends at Regional/Country Levels
AI Disruption Trends
Impact of AI on Industry Verticals
Impact of AI on the Value Chain
Market Spending and Investment
Market Spending and Forecasting Analysis
Venture Capital Investment in AI Focused on Clinical Trials

Chapter 3 Market Dynamics

Market Drivers
Need for a Faster Drug Development Process
AI-driven Clinical Trials
Advanced Data Handling for Complex Clinical Input
Market Restraints
Data Privacy and Security Concerns
Regulatory Uncertainties
High Costs and Technical Complexity
Market Opportunities
Accelerated Trials Through Adaptive AI Design
AI-Augmented Remote Patient Monitoring

Chapter 4 Regulatory Landscape

Regulatory Framework

Chapter 5 Emerging Technologies

Overview
Emerging Technologies
Machine Learning for Predictive Analytics and Stratification
Digital Twin Technology
NLP for Extracting Insights from Unstructured Data
AI-Powered Trial Design and Optimization
Blockchain for Secure Clinical Data Management
Decentralized and Virtual Trial Platforms
Remote Monitoring Via Wearable Technologies
Generative AI for Protocol Authoring
Real-World Evidence Integration in Clinical Trials
Cloud-based AI Platforms for Scalable Deployment
Clinical Trial Analysis
Takeaways

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Global Market for AI in Clinical Trials, by Component
Takeaways
Software
Services
Global AI in Clinical Trials Market, by Phase
Takeaways
Phase III
Phase II Trials
Phase I
Phase IV Clinical Trials
Global Market for AI in Clinical Trials, by Deployment Mode
Takeaways
Cloud
On-premise
Hybrid Deployments
Global Market for AI in Clinical Trials, by Therapeutic Area
Takeaways
Oncology
Infectious Disease Clinical Trials
Neurological Diseases
Other Conditions
Global Market for AI in Clinical Trials, by End User
Takeaways
Pharmaceutical and Biotech Companies
Contract Research Organizations
Research and Academic Institutes
Other End Users
Geographic Breakdown
North America
Europe
Asia-Pacific
Middle East and Africa
South America

Chapter 7 Competitive Intelligence

Overview

Chapter 8 Sustainability in AI in Clinical Trials: ESG Perspective

Sustainability Trends and AI Initiatives
Concluding Remarks

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
AICURE
CONCERTAI
DNANEXUS INC.
INSILICO MEDICINE
INTELLIGENCIA AI
IQVIA
MEDIDATA
MERATIVE
NVIDIA CORP.
PHESI
SAAMA
TEMPUS
TRINETX LLC
TRIOMICS
UNLEARN.AI INC.
Emerging Start-ups/ Market Disruptors

簡介目錄圖表

List of Tables

Summary Table : Global Market for AI in Clinical Trials, by Region, Through 2030
Table 1 : Real GDP Growth, by Country, 2022-2025
Table 2 : Venture Capital Funding for U.S. Companies on AI for Clinical Trials
Table 3 : VC Investment in AI Focused on Clinical Trials
Table 4 : Regulations Pertaining to AI in Clinical Trials
Table 5 : Clinical Trials Studies
Table 6 : Global Market for AI in Clinical Trials, by Component, Through 2030
Table 7 : Global Market for AI Software in Clinical Trials, by Region, Through 2030
Table 8 : Global Market for Services Related to AI in Clinical Trials, by Region, Through 2030
Table 9 : Global Market for AI in Clinical Trials, by Phase, Through 2030
Table 10 : Global Market for AI in Phase III Clinical Trials, by Region, Through 2030
Table 11 : Global Market for AI in Phase II Clinical Trials, by Region, Through 2030
Table 12 : Global Market for AI in Phase I Clinical Trials, by Region, Through 2030
Table 13 : Global Market for AI in Phase IV Clinical Trials, by Region, Through 2030
Table 14 : Global Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 15 : Global Market for Cloud Deployments of AI in Clinical Trials, by Region, Through 2030
Table 16 : Global Market for On-Premise Deployments of AI in Clinical Trials, by Region, Through 2030
Table 17 : Global Market for Hybrid Deployments of AI in Clinical Trials, by Region, Through 2030
Table 18 : Global Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 19 : Global Market for AI in Oncology Clinical Trials, by Region, Through 2030
Table 20 : Global Market for AI in Infectious Disease Clinical Trials, by Region, Through 2030
Table 21 : Global Market for AI in Neurological Disease Clinical Trials, by Region, Through 2030
Table 22 : Global Market for AI in Clinical Trials for Other Conditions, by Region, Through 2030
Table 23 : Global Market for AI in Clinical Trials, by End User, Through 2030
Table 24 : Global Market for AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, Through 2030
Table 25 : Global Market for AI Used in Clinical Trials by CROs, by Region, Through 2030
Table 26 : Global Market for AI Used in Clinical Trials by Research and Academic Institutes, by Region, Through 2030
Table 27 : Global Market for AI Used by Other End Users in Clinical Trials, by Region, Through 2030
Table 28 : Global Market for AI in Clinical Trials, by Region, Through 2030
Table 29 : North American Market for AI in Clinical Trials, by Component, Through 2030
Table 30 : North American Market for AI in Clinical Trials, by Phase, Through 2030
Table 31 : North American Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 32 : North American Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 33 : North American Market for AI in Clinical Trials, by End User, Through 2030
Table 34 : North American Market for AI in Clinical Trials, by Country, Through 2030
Table 35 : European Market for AI in Clinical Trials, by Component, Through 2030
Table 36 : European Market for AI in Clinical Trials, by Phase, Through 2030
Table 37 : European Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 38 : European Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 39 : European Market for AI in Clinical Trials, by End User, Through 2030
Table 40 : European Market for AI in Clinical Trials, by Country, Through 2030
Table 41 : Asia-Pacific Market for AI in Clinical Trials, by Component, Through 2030
Table 42 : Asia-Pacific Market for AI in Clinical Trials, by Phase, Through 2030
Table 43 : Asia-Pacific Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 44 : Asia-Pacific Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 45 : Asia-Pacific Market for AI in Clinical Trials, by End User, Through 2030
Table 46 : Asia-Pacific Market for AI in Clinical Trials, by Country, Through 2030
Table 47 : MEA Market for AI in Clinical Trials, by Component, Through 2030
Table 48 : MEA Market for AI in Clinical Trials, by Phase, Through 2030
Table 49 : MEA Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 50 : MEA Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 51 : MEA Market for AI in Clinical Trials, by End User, Through 2030
Table 52 : MEA Market for AI in Clinical Trials, by Sub-Region, Through 2030
Table 53 : South American Market for AI in Clinical Trials, by Component, Through 2030
Table 54 : South American Market for AI in Clinical Trials, by Phase, Through 2030
Table 55 : South American Market for AI in Clinical Trials, by Deployment Mode,Through 2030
Table 56 : South American Market for AI in Clinical Trials, by Therapeutic Area,Through 2030
Table 57 : South American Market for AI in Clinical Trials, by End User, Through 2030
Table 58 : South American Market for AI in Clinical Trials, by Country, Through 2030
Table 59 : Global Ranking of Players in AI in Clinical Trials Industry, 2024
Table 60 : Strategic Initiatives, 2024 and 2025
Table 61 : Information Sources Used in Preparing this Report
Table 62 : Abbreviations Used in this Report
Table 63 : AiCure: Company Snapshot
Table 64 : AiCure: Product Portfolio
Table 65 : AiCure: News/Key Developments, 2022
Table 66 : ConcertAI: Company Snapshot
Table 67 : ConcertAI: Product Portfolio
Table 68 : ConcertAI: News/Key Developments, 2023 and 2024
Table 69 : DNAnexus Inc.: Company Snapshot
Table 70 : DNAnexus Inc: Product Portfolio
Table 71 : DNAnexus Inc: News/Key Developments, 2024 and 2025
Table 72 : Insilico Medicine: Company Snapshot
Table 73 : Insilico Medicine: Product Portfolio
Table 74 : Insilico Medicine: News/Key Developments, 2023-2025
Table 75 : Intelligencia AI: Company Snapshot
Table 76 : Intelligencia AI: Product Portfolio
Table 77 : IQVIA: Company Snapshot
Table 78 : IQVIA: Financial Performance, FY 2023 and 2024
Table 79 : IQVIA: Product Portfolio
Table 80 : IQVIA: News/Key Developments, 2025
Table 81 : Medidata: Company Snapshot
Table 82 : Medidata: Product Portfolio
Table 83 : Medidata: News/Key Developments, 2023-2025
Table 84 : Merative: Company Snapshot
Table 85 : Merative: Product Portfolio
Table 86 : Nvidia Corp.: Company Snapshot
Table 87 : Nvidia Corp.: Financial Performance, FY 2023 and 2024
Table 88 : Nvidia Corp.: Product Portfolio
Table 89 : Nvidia Corp.: News/Key Developments, 2023-2025
Table 90 : Phesi: Company Snapshot
Table 91 : Phesi: Product Portfolio
Table 92 : Phesi: News/Key Developments, 2022-2025
Table 93 : Saama: Company Snapshot
Table 94 : Saama: Product Portfolio
Table 95 : Saama: News/Key Developments, 2023 and 2024
Table 96 : Tempus: Company Snapshot
Table 97 : Tempus: Product Portfolio
Table 98 : Tempus: News/Key Developments, 2022-2025
Table 99 : TriNetX LLC.: Company Snapshot
Table 100 : TriNetX LLC: Product Portfolio
Table 101 : TriNetX LLC: News/Key Developments, 2025
Table 102 : Triomics: Company Snapshot
Table 103 : Triomics: Product Portfolio
Table 104 : Unlearn.ai Inc.: Company Snapshot
Table 105 : Unlearn.ai Inc.: Product Portfolio
Table 106 : Unlearn.ai Inc.: News/Key Developments, 2022 and 2025
Table 107 : Emerging Startups

List of Figures

Summary Figure : Global Market Shares of AI in Clinical Trials, by Region, 2024
Figure 1 : Porter's Five Forces Analysis
Figure 2 : Market Dynamics of Artificial Intelligence in Clinical Trials Market
Figure 3 : Global Market Shares of AI in Clinical Trials, by Component, 2024
Figure 4 : Global Market Shares of AI Software in Clinical Trials, by Region, 2024
Figure 5 : Global Market Shares of Services Related to AI in Clinical Trials, by Region, 2024
Figure 6 : Global Market Shares of AI in Clinical Trials, by Phase, 2024
Figure 7 : Global Market Shares of AI in Phase III Clinical Trials, by Region, 2024
Figure 8 : Global Market Shares of AI in Phase II Clinical Trials, by Region, 2024
Figure 9 : Global Market Shares of AI in Phase I Clinical Trials, by Region, 2024
Figure 10 : Global Market Shares of AI in Phase IV Clinical Trials, by Region, 2024
Figure 11 : Global Market Shares of AI in Clinical Trials, by Deployment Mode, 2024
Figure 12 : Global Market Shares of Cloud Deployments of AI in Clinical Trials, by Region, 2024
Figure 13 : Global Market Shares of On-Premise Deployments of AI in Clinical Trials, by Region, 2024
Figure 14 : Global Market Shares of Hybrid Deployments of AI in Clinical Trials, by Region, 2024
Figure 15 : Global Market Shares of AI in Clinical Trials, by Therapeutic Area, 2024
Figure 16 : Global Market Shares of AI in Oncology Clinical Trials, by Region, 2024
Figure 17 : Global Market Shares of AI in Infectious Disease Clinical Trials, by Region, 2024
Figure 18 : Global Market Shares of AI in Neurological Disease Clinical Trials, by Region, 2024
Figure 19 : Global Market Shares of AI in Clinical Trials for Other Conditions, by Region, 2024
Figure 20 : Global Market Shares of AI in Clinical Trials, by End User, 2024
Figure 21 : Global Market Shares of AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, 2024
Figure 22 : Global Market Shares of AI Used in Clinical Trials by CROs, by Region, 2024
Figure 23 : Global Market Shares of AI Used in Clinical Trials by Research and Academic Institutes, by Region, 2024
Figure 24 : Global Market Shares of AI Used by Other End Users in Clinical Trials, by Region, 2024
Figure 25 : Global Market Shares of AI in Clinical Trials, by Region, 2024
Figure 26 : North American Market Shares of AI in Clinical Trials, by Country, 2024
Figure 27 : European Market Shares of AI in Clinical Trials, by Country, 2024
Figure 28 : Asia-Pacific Market Shares of AI in Clinical Trials, by Country, 2024
Figure 29 : MEA Market Shares of AI in Clinical Trials, by Sub-Region, 2024
Figure 30 : South American Market Shares of AI in Clinical Trials, by Country, 2024
Figure 31 : IQVIA: Revenue Shares, by Business Unit, FY 2024
Figure 32 : IQVIA: Revenue Shares, by Country/Region, FY 2024
Figure 33 : Nvidia Corp.: Revenue Share, by Business Unit, FY 2024
Figure 34 : Nvidia Corp.: Revenue Share, by Country/Region, FY 2024